Sandoz is seeking an injunction to prevent Amgen from using certain patent rights to block biosimilar competition and allow ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesCompany aims to accelerate access to much-needed biosimilar to reference ...

Sandoz has filed an antitrust lawsuit in the United States against Amgen, for extending and entrenching the dominant market ...

oIncreasing demand for biologics in rheumatoid arthritis treatment. oGreater awareness of conditions such as ulcerative colitis and ankylosing spondylitis. oImproved patient outcomes due to ...

Sandoz sues Amgen in U.S. court over Enbrel patents, alleging efforts to block biosimilar Erelzi and delay competition in the ...

Tyler J. Ashton is biking across Canada through biting winter winds and freezing rain, turning his daily battle with chronic ...

Sandoz (SDZNY) announced the filing of an antitrust lawsuit in the U.S. against Amgen (AMGN), for extending and entrenching the dominant market ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules - corrected: reference to date of product launch in Europe removed; link to "Important Safety Information" updated Company aims ...

Biologic treatments ... Psoriatic Arthritis; Ankylosing Spondylitis; Plaque 2 Route of Administration: Subcutaneous Injection; Intravenous 3 Distribution Channel: Hospital Pharmacies; Online ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...